RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

SAN FRAN­CIS­CO — RTW In­vest­ments is once again pro­vid­ing fund­ing to Ji Xing Phar­ma­ceu­ti­cals, the Shang­hai-based biotech it in­cu­bat­ed in 2019, with $127 mil­lion along­side a $35 mil­lion in­vest­ment from Bay­er’s Leaps by Bay­er unit.

The Se­ries D fi­nanc­ing, dis­closed in the week­end lead­ing up to the JP Mor­gan Health­care Con­fer­ence, could al­so bear fruit for Bay­er’s car­dio­vas­cu­lar and oph­thal­mol­o­gy pipeline, as the multi­na­tion­al Big Phar­ma snags the “priv­i­leged rights to ne­go­ti­ate the com­mer­cial­iza­tion of Ji Xing’s pipeline as­sets” in those broad ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.